NO20092385L - Indolderivater som S1P1 receptoragonister - Google Patents

Indolderivater som S1P1 receptoragonister

Info

Publication number
NO20092385L
NO20092385L NO20092385A NO20092385A NO20092385L NO 20092385 L NO20092385 L NO 20092385L NO 20092385 A NO20092385 A NO 20092385A NO 20092385 A NO20092385 A NO 20092385A NO 20092385 L NO20092385 L NO 20092385L
Authority
NO
Norway
Prior art keywords
receptor agonists
indole derivatives
receptor
sip
hydrogen
Prior art date
Application number
NO20092385A
Other languages
English (en)
Norwegian (no)
Inventor
Mahmood Ahmed
James Myatt
David Norton
Dean Andrew Rivers
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39283563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092385(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0625647A external-priority patent/GB0625647D0/en
Priority claimed from GB0707615A external-priority patent/GB0707615D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20092385L publication Critical patent/NO20092385L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
NO20092385A 2006-12-21 2009-06-23 Indolderivater som S1P1 receptoragonister NO20092385L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0625647A GB0625647D0 (en) 2006-12-21 2006-12-21 Compounds
GB0707615A GB0707615D0 (en) 2007-04-19 2007-04-19 Compounds
PCT/EP2007/064185 WO2008074821A1 (en) 2006-12-21 2007-12-19 Indole derivatives as s1p1 receptor agonists

Publications (1)

Publication Number Publication Date
NO20092385L true NO20092385L (no) 2009-08-24

Family

ID=39283563

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092385A NO20092385L (no) 2006-12-21 2009-06-23 Indolderivater som S1P1 receptoragonister

Country Status (32)

Country Link
US (1) US8101775B2 (en:Method)
EP (2) EP2091949B1 (en:Method)
JP (1) JP5309034B2 (en:Method)
KR (1) KR101495927B1 (en:Method)
CN (1) CN103012390B (en:Method)
AR (1) AR064452A1 (en:Method)
AT (1) ATE509927T1 (en:Method)
AU (1) AU2007336224B2 (en:Method)
BR (1) BRPI0721127A2 (en:Method)
CA (1) CA2673468C (en:Method)
CL (1) CL2007003755A1 (en:Method)
CR (2) CR10922A (en:Method)
CY (2) CY1111702T1 (en:Method)
DK (2) DK2206710T3 (en:Method)
DO (1) DOP2009000133A (en:Method)
EA (1) EA017406B1 (en:Method)
ES (1) ES2389879T3 (en:Method)
HR (2) HRP20110456T1 (en:Method)
IL (1) IL199187A (en:Method)
JO (1) JO2701B1 (en:Method)
MA (1) MA30999B1 (en:Method)
MX (1) MX2009006882A (en:Method)
MY (2) MY148470A (en:Method)
NO (1) NO20092385L (en:Method)
NZ (1) NZ577387A (en:Method)
PE (2) PE20121076A1 (en:Method)
PL (2) PL2091949T3 (en:Method)
PT (2) PT2206710E (en:Method)
SG (1) SG177914A1 (en:Method)
SI (2) SI2206710T1 (en:Method)
TW (1) TWI393564B (en:Method)
WO (1) WO2008074821A1 (en:Method)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007116866A1 (ja) 2006-04-03 2007-10-18 Astellas Pharma Inc. ヘテロ化合物
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
NZ579595A (en) * 2007-04-19 2012-06-29 Glaxo Group Ltd Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
DK2291080T3 (en) 2008-05-14 2015-12-07 Scripps Research Inst Novel modulator of sphingosinphosphatreceptorer
WO2009151621A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
WO2009151626A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
JP2011524880A (ja) * 2008-06-20 2011-09-08 グラクソ グループ リミテッド 化合物
KR20190004843A (ko) 2008-07-23 2019-01-14 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
MX2011000881A (es) * 2008-07-23 2011-03-02 Novartis Ag Moduladores de los receptores de esfingosina-1-fosfato y su uso para tratar inflamacion muscular.
AU2009288738B9 (en) * 2008-08-27 2015-04-16 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
MX2011006560A (es) 2008-12-18 2011-08-03 Merck Serono Sa Derivados heterociclicos fucionados con oxadiazola utiles para el tratamiento de esclerosis multiple.
EP2202232A1 (en) * 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
GB0910689D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0910667D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
WO2011005295A1 (en) * 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
UA107360C2 (en) * 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
JP5650233B2 (ja) 2009-11-13 2015-01-07 レセプトス インコーポレイテッドＲｅｃｅｐｔｏｓ， Ｉｎｃ． 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2013514280A (ja) * 2009-12-18 2013-04-25 グラクソ グループ リミテッド スフィンゴシン１−リン酸１（ｓ１ｐ１）受容体アゴニストとして使用するためのオキサジアゾール置換インダゾール誘導体
SG10201500639TA (en) 2010-01-27 2015-03-30 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
SG183416A1 (en) * 2010-03-03 2012-09-27 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2560969B1 (en) 2010-04-23 2015-08-12 Bristol-Myers Squibb Company 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists
JP5869579B2 (ja) 2010-09-24 2016-02-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用
ES2602173T3 (es) 2011-02-07 2017-02-17 Biogen Ma Inc. Agentes moduladores S1P
JP6129159B2 (ja) 2011-05-13 2017-05-17 レセプトス エルエルシー 選択的複素環式スフィンゴシン１−リン酸受容体モジュレーター
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GB201202027D0 (en) * 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
KR102481328B1 (ko) * 2016-07-22 2022-12-26 메드샤인 디스커버리 아이엔씨. S1p1 작용제 및 이의 응용
CA3038106A1 (en) * 2016-09-29 2018-04-05 Celgene International Ii Sarl Compounds and methods for treating lupus
CA3053416A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
CN110627778B (zh) * 2018-06-25 2023-01-24 中国科学院上海药物研究所 一类含有1,2,4-噁二唑环的化合物、其制备方法及其在免疫抑制药物中的应用
CN119751336A (zh) 2018-09-06 2025-04-04 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物
WO2021084068A1 (en) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021112461A1 (ko) 2019-12-03 2021-06-10 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물
BR112022015723A2 (pt) * 2020-02-11 2023-02-14 Syngenta Crop Protection Ag Compostos de amina cíclica pesticidamente ativos
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939238A1 (de) 1989-11-28 1991-05-29 Bayer Ag Heterocyclisch substituierte acrylsaeureester
DE4002466A1 (de) 1990-01-28 1991-10-10 Bayer Ag Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester
US5523312A (en) 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
WO2003105771A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
JP2006528980A (ja) * 2003-05-15 2006-12-28 メルク　エンド　カムパニー　インコーポレーテッド Ｓ１ｐ受容体作働薬としての３−（２−アミノ−１−アザシクロ）−５−アリール−１，２，４−オキサジアゾール類
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
CA2539438A1 (en) * 2003-10-01 2005-04-14 Merck And Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
WO2005058848A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
WO2006001463A1 (ja) 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Ｓ１ｐ受容体結合能を有する化合物およびその用途
EP1804793A4 (en) 2004-10-22 2010-03-31 Merck Sharp & Dohme 2- (ARYL) AZACYCLYLMETHYL-CARBOXYLATE, SULPHONATE, PHOSPHONATE, PHOSPHINATE AND HETEROCYCLES AS S1P RECEPTOR AGONISTS
WO2006090817A1 (ja) 2005-02-25 2006-08-31 Ono Pharmaceutical Co., Ltd. インドール化合物およびその用途
US7605269B2 (en) 2005-03-23 2009-10-20 Actelion Pharmaceuticals Ltd. Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists
NZ563522A (en) 2005-04-22 2010-01-29 Daiichi Sankyo Co Ltd Heterocyclic compound with immunosuppressive activity
US20080306124A1 (en) 2005-06-08 2008-12-11 Rainer Albert Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands
JP2009506046A (ja) 2005-08-23 2009-02-12 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制剤化合物および組成物
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
JP2007262009A (ja) 2006-03-29 2007-10-11 Dai Ichi Seiyaku Co Ltd ヘテロアリール低級カルボン酸誘導体
WO2007116866A1 (ja) * 2006-04-03 2007-10-18 Astellas Pharma Inc. ヘテロ化合物
CN101511827B (zh) 2006-09-07 2012-02-01 埃科特莱茵药品有限公司 作为免疫调制剂的吡啶-4-基衍生物
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
NZ579595A (en) * 2007-04-19 2012-06-29 Glaxo Group Ltd Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists

Also Published As

Publication number Publication date
HK1140761A1 (en) 2010-10-22
PL2206710T3 (pl) 2012-11-30
AR064452A1 (es) 2009-04-01
CN103012390B (zh) 2015-08-26
CN103012390A (zh) 2013-04-03
PT2206710E (pt) 2012-09-10
DK2091949T3 (da) 2011-07-18
JO2701B1 (en) 2013-03-03
JP2010513397A (ja) 2010-04-30
EA200970612A1 (ru) 2009-10-30
ES2389879T3 (es) 2012-11-02
SG177914A1 (en) 2012-02-28
IL199187A0 (en) 2010-03-28
CY1111702T1 (el) 2015-10-07
SI2206710T1 (sl) 2012-10-30
SI2091949T1 (sl) 2011-08-31
CY1113131T1 (el) 2016-04-13
EP2091949B1 (en) 2011-05-18
TW200843736A (en) 2008-11-16
WO2008074821A1 (en) 2008-06-26
JP5309034B2 (ja) 2013-10-09
KR101495927B1 (ko) 2015-02-25
HK1130255A1 (en) 2009-12-24
CL2007003755A1 (es) 2008-08-22
EP2206710A1 (en) 2010-07-14
NZ577387A (en) 2012-01-12
CA2673468C (en) 2015-06-02
AU2007336224B2 (en) 2013-01-10
CR20140316A (es) 2014-08-20
EA017406B1 (ru) 2012-12-28
HRP20110456T1 (hr) 2011-07-31
EP2206710B1 (en) 2012-07-04
PE20121076A1 (es) 2012-09-05
EP2091949A1 (en) 2009-08-26
US8101775B2 (en) 2012-01-24
PE20081398A1 (es) 2008-11-19
ATE509927T1 (de) 2011-06-15
HRP20120685T1 (hr) 2012-09-30
PL2091949T3 (pl) 2011-10-31
KR20090092290A (ko) 2009-08-31
MA30999B1 (fr) 2009-12-01
IL199187A (en) 2015-04-30
BRPI0721127A2 (pt) 2014-03-11
CA2673468A1 (en) 2008-06-26
DOP2009000133A (es) 2009-08-15
DK2206710T3 (da) 2012-08-27
US20100113796A1 (en) 2010-05-06
CR10922A (es) 2009-08-12
MX2009006882A (es) 2009-07-03
AU2007336224A1 (en) 2008-06-26
MY148470A (en) 2013-04-30
MY156822A (en) 2016-03-31
TWI393564B (zh) 2013-04-21
PT2091949E (pt) 2011-07-13

Similar Documents

Publication Publication Date Title
NO20092385L (no) Indolderivater som S1P1 receptoragonister
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
NO20090738L (no) Tilveiebringelse av EP2 agonister, fremgangsmate for fremstilling derav, farmasoytiske sammensetninger inneholdende disse forbindelser og fremgangsmater for anvendelse av forbindelsene og sammensetningene for a senke intraokkulaert trykk og behandle glaukom
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
NO20091326L (no) Indazolderivater som modulatorer av interleukin-1-reseptor-assosiert kinase
NO20084850L (no) MGLUR5 modulatorer I
CL2008001017A1 (es) Compuestos derivados de indol, activadores de glucoquinasa; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de diabetes u obesidad.
NO20084924L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
NO20083246L (no) Nye benzimidazolderivater som vanilloid-reseptor 1 (VRL) inhibitorer
NO20090266L (no) Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer
CL2011000919A1 (es) Compuestos derivados de n-fenil-4-oxo-(1,4-dihidroquinolin o 1h-quinolin)-3-carboxamida, moduladores del regulador de conductancia transmembrana de fibrosis quistica (cftr); compuestos intermediarios; composicion farmaceutica; kit farmaceutico; proceso de preparacion; y uso para el tratamiento de fibrosis quistica, diabetes, entre otros.
NO20084278L (no) Bezothiazol derivatives as beta2 adrenoreceptor agonists
NO20084307L (no) Heterocykliske GPCR agonister
PE20091425A1 (es) Derivados de aminotiazol
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
WO2008076243A3 (en) Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
NO20076479L (no) Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer
NO20085031L (no) Benzimidazolmodulatorer av VR1
MX2009013676A (es) Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa.
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
NO20081983L (no) Nye azetidinforbindelser nyttige i behandlingen av funksjonelle gastrointestinale forstyrrelser, IBS og funksjonell dyspepsi
NO20084852L (no) MGLUR5 modulatorer V
JO2749B1 (en) Indole-2-Wen derivatives bilaterally substituted at position 3, their preparation and therapeutic application
NO20073652L (no) Enantiomerer av 3-heteroaryl-8H-8-azabisyklo(3.2.1)okt-2-en og deres anvendelse som monoaminnevrotransmitter-gjenopptaksinhibitorer

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application